Tralokinumab is a fully human monoclonal antibody designed to treat moderate to severe atopic dermatitis (AD) by specifically neutralizing interleukin-13 (IL-13), a key cytokine driving the peripheral inflammation characteristic of AD. Its efficacy and safety have been evaluated in several clinical trials, making it a significant advancement in the management of AD. Tralokinumab represents a significant advancement in the treatment of moderate to severe atopic dermatitis, offering a new therapeutic option for patients who have not responded adequately to conventional therapies. Its ability to specifically target IL-13 and its demonstrated efficacy in improving both the physical symptoms and quality of life for patients with AD underscore its value in dermatological care.